Application of Nanocarrier Systems in the Treatment of Multiple Sclerosis

Abstract

Numerous factors need to be taken into consideration in the treatment of Multiple Sclerosis (MS), which has a complex immunopathology among neurodegenerative diseases. Clinical findings in this multifactorial disease depend on the progression of myelin loss, the stage of inflammation, the status of axons, and the activity of oligodendrocyte precursor cells. Despite intensive studies for many years, a definitive treatment has yet to be found due to the multifactorial nature of the disease and structures, such as the blood-brain barrier (BBB) that prevents drugs from reaching the brain. This situation has led scientists to search for new approaches. Studies have shown that nanosized pharmaceutical carriers, often called nanocarriers, might play a role not only in the diagnosis but also in the treatment of MS. Studies are continuing intensively to transition these systems, which have been shown to be successful in preclinical in vitro and in vivo studies for the treatment of MS, to clinical application. In this review, the most current developments in the literature on nanocarriers for MS treatment are evaluated.

Keywords

• Multiple Sclerosis
• blood-brain barrier
• drug delivery system
• nanocarrier
• nanoparticle

Project Number

Yok

Multipl Skleroz Tedavisinde Nanotaşıyıcı Sistemlerin Uygulanması

Abstract

Nörodejeneratif hastalıklar arasında kompleks bir immünopatolojiye sahip olan Multipl Skleroz (MS)’un tedavisinde birçok faktörün dikkate alınması gerekmektedir. Bu çok faktörlü hastalıktaki klinik bulgular miyelin kaybının ilerlemesine, enflamasyonun evresine, aksonların durumuna ve oligodendrosit öncü hücrelerinin aktivitesine bağlıdır. Uzun yıllardır süregelen yoğun çalışmalara rağmen hastalığın çok faktörlü oluşu ve kan-beyin engeli (KBE) gibi ilaçların beyne ulaşmasını engelleyen yapılar nedeniyle henüz kesin bir tedavi bulunamamıştır. Bu durum, bilim insanlarını yeni yaklaşımlar aramaya yönlendirmiştir. Yapılan araştırmalarda genellikle nanotaşıyıcı olarak adlandırılan nano boyuttaki farmasötik taşıyıcıların MS’nin yalnızca teşhisinde değil aynı zamanda tedavisinde de rolüstlenebileceğini göstermiştir. MS’nin tedavisi için klinik öncesi in vitro ve in vivo çalışmalarla başarılı olduğu gösterilen bu sistemlerin klinik uygulamaya geçiş yapabilmesi için çalışmalar yoğun bir şekilde devam etmektedir. Bu derlemede MS tedavisine yönelik nanotaşıyıcılar konusunda literatürde yer alan en güncel gelişmeler değerlendirilmiştir.

Keywords

• Multipl Skleroz
• kan-beyin engeli
• ilaç taşıyıcı sistem
• nanotaşıyıcı
• nanopartikül

Supporting Institution

Yok

Project Number

Yok

Ethical Statement

Yok

Thanks

Yok

References

1. 1. Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J Control Release 2018;270:89–100. https://doi.org/10.1016/j. jconrel.2017.11.047
2. 2. Rayatpour A, Javan M. Targeting the brain lesions using pep- tides: A review focused on the possibility of targeted drug de- livery to multiple sclerosis lesions. Pharmacological Research 2021;167:105441. https://doi.org/10.1016/j.phrs.2021.105441
3. 3. J. van der Star B, Y.S. Vogel D, Kipp M, Puentes F, Ba- ker D, Amor S. In Vitro and In Vivo Models of Multip- le Sclerosis. CNSNDDT 2012;11:570–88. https://doi. org/10.2174/187152712801661284
4. 4. Martínez-Larrosa J, Matute-Blanch C, Montalban X, Comabel- la M. Modelling multiple sclerosis using induced pluripotent stem cells. Journal of Neuroimmunology 2020;349:577425. https://doi.org/10.1016/j.jneuroim.2020.577425
5. 5. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwi- de: Insights from the Atlas of MS, third edition. Mult Scler 2020;26:1816–21. https://doi.org/10.1177/1352458520970841
6. 6. Bechtel MA, Wong HK. Neurologic adverse effects from der- matologic drugs. Comprehensive Dermatologic Drug Therapy, Elsevier; 2013, p. 711-717.e2. https://doi.org/10.1016/B978- 1-4377-2003-7.00063-7
7. 7. Dolati S, Babaloo Z, Jadidi-Niaragh F, Ayromlou H, Sadreddi- ni S, Yousefi M. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems. Biomedicine & Pharma- cotherapy 2017;86:343–53. https://doi.org/10.1016/j.biop- ha.2016.12.010
8. 8. Gadhave DG, Sugandhi VV, Kokare CR. Potential bioma- terials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis. Brain Research 2023:148674. https://doi. org/10.1016/j.brainres.2023.148674

9. 9. Tabansky I, Messina MD, Bangeranye C, Goldstein J, Blitz- Shabbir KM, Machado S, et al. Advancing drug delivery systems for the treatment of multiple sclerosis. Immunol Res 2015;63:58–69. https://doi.org/10.1007/s12026-015-8719-0
10. 10. Wei W, Ma D, Li L, Zhang L. Progress in the Application of Drugs for the Treatment of Multiple Sclerosis. Front Pharmacol 2021;12:724718. https://doi.org/10.3389/fphar.2021.724718
11. 11. Zadeh AR, Askari M, Azadani NN, Ataei A, Ghadimi K, Fala- hatian M. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1. Int J Physiol Pathophysiol Phar- macol 2019;11:95–104
12. 12. Barbieri MA, Sorbara EE, Battaglia A, Cicala G, Rizzo V, Spina E, et al. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovi- gilance Database. Front Pharmacol 2022;13:808370. https:// doi.org/10.3389/fphar.2022.808370
13. 13. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers 2018;4:43. https://doi.org/10.1038/s41572-018-0041-4
14. 14. Correale J, Halfon MJ, Jack D, Rubstein A, Villa A. Ac- ting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Multiple Sclerosis and Rela- ted Disorders 2021;56:103264. https://doi.org/10.1016/j. msard.2021.103264
15. 15. Mwema A, Muccioli GG, des Rieux A. Innovative drug de- livery strategies to the CNS for the treatment of multiple sclerosis. J Control Release 2023;364:435–57. https://doi. org/10.1016/j.jconrel.2023.10.052
16. 16. Misra A, Ganesh S, Shahiwala A. Drug Delivery To The Central Nervous System: A Review. J Pharm Pharm Sci 2003;6:252–73
17. 17. Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Ca- ruso F. Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Advan- ced Materials 2018;30:1801362. https://doi.org/10.1002/ adma.201801362
18. 18. Pardridge WM. CSF, blood-brain barrier, and brain drug de- livery. Expert Opinion on Drug Delivery 2016;13:963–75. https://doi.org/10.1517/17425247.2016.1171315
19. 19. Kadry H, Noorani B, Cucullo L. A blood–brain barrier over- view on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 2020;17:69. https://doi. org/10.1186/s12987-020-00230-3
20. 20. Rahiman N, Mohammadi M, Alavizadeh SH, Arabi L, Badiee A, Jaafari MR. Recent advancements in nanoparticle-media- ted approaches for restoration of multiple sclerosis. J Control Release 2022;343:620–44. https://doi.org/10.1016/j.jcon- rel.2022.02.009
21. 21. Quintana FJ. Nanoparticles for the induction of antigen- specific Tregs. Immunotherapy 2013;5:437–40. https://doi. org/10.2217/imt.13.25
22. 22. Soica C, Coricovac D, Dehelean C, Pinzaru I, Mioc M, Danciu C, et al. Nanocarriers as Tools in Delivering Active Compo- unds for Immune System Related Pathologies. NANOTEC 2016;10:128–45. https://doi.org/10.2174/1872210510999160 427113345
23. 23. Serra P, Santamaria P. Nanoparticle-based autoimmune dise- ase therapy. Clinical Immunology 2015;160:3–13. https://doi. org/10.1016/j.clim.2015.02.003
24. 24. Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, et al. Nanotechnology-based drug delivery systems for Alzheimer’s disease management: Technical, industrial, and clinical challenges. J Control Release 2017;245:95–107. https://doi.org/10.1016/j.jcon- rel.2016.11.025
25. 25. Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 2013;166:182–94. https://doi. org/10.1016/j.jconrel.2012.12.013
26. 26. Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanopartic- les for delivery of drugs across the blood–brain barrier. WI- REs Nanomed Nanobiotechnol 2009;1:463–74. https://doi. org/10.1002/wnan.5
27. 27. Annu, Sartaj A, Qamar Z, Md S, Alhakamy NA, Baboota S, et al. An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurolo- gical Disorders and Brain Tumor. Front Bioeng Biotechnol 2022;10:788128. https://doi.org/10.3389/fbioe.2022.788128
28. 28. Mittal P, Saharan A, Verma R, Altalbawy FMA, Alfaidi MA, Batiha GE-S, et al. Dendrimers: A New Race of Phar- maceutical Nanocarriers. BioMed Research International 2021;2021:1–11. https://doi.org/10.1155/2021/8844030
29. 29. Chauhan A. Dendrimers for Drug Delivery. Molecules 2018;23:938. https://doi.org/10.3390/molecules23040938
30. 30. Pérez-Carrión MD, Posadas I. Dendrimers in Neurodegenera- tive Diseases. Processes 2023;11:319. https://doi.org/10.3390/ pr11020319
31. 31. Kaur A, Singh N, Kaur H, Kakoty V, Sharma DS, Khursheed R, et al. Neurodegenerative diseases and brain delivery of the- rapeutics: Bridging the gap using dendrimers. Journal of Drug Delivery Science and Technology 2023;87:104868. https://doi. org/10.1016/j.jddst.2023.104868
32. 32. Sherje AP, Jadhav M, Dravyakar BR, Kadam D. Dendrimers: A versatile nanocarrier for drug delivery and targeting. Interna- tional Journal of Pharmaceutics 2018;548:707–20. https://doi. org/10.1016/j.ijpharm.2018.07.030
33. 33. Wang Y, Ying X, Xu H, Yan H, Li X, Tang H. The functio- nal curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals. IJN 2017;Volume 12:1369–84. https://doi.org/10.2147/IJN. S124276
34. 34. Ciani L, Ristori S, Salvati A, Calamai L, Martini G. DOTAP/ DOPE and DC-Chol/DOPE lipoplexes for gene delivery: zeta potential measurements and electron spin resonan- ce spectra. Biochimica et Biophysica Acta (BBA) - Bio- membranes 2004;1664:70–9. https://doi.org/10.1016/j.bba- mem.2004.04.003
35. 35. Barbara R, Belletti D, Pederzoli F, Masoni M, Keller J, Bal- lestrazzi A, et al. Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. International Journal of Phar- maceutics 2017;526:413–24. https://doi.org/10.1016/j.ijp- harm.2017.05.015
36. 36. Gajbhiye KR, Pawar A, Mahadik KR, Gajbhiye V. PEGylated nanocarriers: A promising tool for targeted delivery to the bra- in. Colloids and Surfaces B: Biointerfaces 2020;187:110770. https://doi.org/10.1016/j.colsurfb.2019.110770
37. 37. Patel S, Chavhan S, Soni H, Babbar AK, Mathur R, Mish- ra AK, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. Journal of Drug Tar- geting 2011;19:468–74. https://doi.org/10.3109/106118 6X.2010.523787
38. 38. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Do- latabadi JEN, Omidfar K. Drug targeting using solid lipid na- noparticles. Chemistry and Physics of Lipids 2014;181:56–61. https://doi.org/10.1016/j.chemphyslip.2014.03.006
39. 39. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Re- lease 2008;127:97–109. https://doi.org/10.1016/j.jcon- rel.2007.12.018
40. 40. Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv 2020;10:26777–91. https://doi.org/10.1039/D0RA03491F
41. 41. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanopar- ticles and nanostructured lipid carriers as novel drug deli- very systems: applications, advantages and disadvantages. Res Pharma Sci 2018;13:288. https://doi.org/10.4103/1735- 5362.235156
42. 42. Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant poten- tial for dermal applications. International Journal of Nanome- dicine 2012;7:1841–50
43. 43. Hernández-Esquivel R-A, Navarro-Tovar G, Zárate- Hernández E, Aguirre-Bañuelos P. Solid Lipid Nanoparticles (SLN). In: Sharma A, editor. Nanocomposite Materials for Biomedical and Energy Storage Applications, Rijeka: Intec- hOpen; 2022. https://doi.org/10.5772/intechopen.102536
44. 44. Gugleva V, Andonova V. Recent Progress of Solid Lipid Na- noparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms. Pharmaceuticals 2023;16:474. https://doi. org/10.3390/ph16030474
45. 45. Moraes AS, Paula RFO, Pradella F, Santos MPA, Oliveira EC, von Glehn F, et al. The Suppressive Effect of IL -27 on Encep- halitogenic Th17 Cells Induced by Multiwalled Carbon Nano- tubes Reduces the Severity of Experimental Autoimmune En- cephalomyelitis. CNS Neurosci Ther 2013;19:682–7. https:// doi.org/10.1111/cns.12121
46. 46. Singh AV, Khare M, Gade WN, Zamboni P. Theranostic Imp- lications of Nanotechnology in Multiple Sclerosis: A Future Perspective. Autoimmune Diseases 2012;2012:1–12. https:// doi.org/10.1155/2012/160830
47. 47. Bolskar R. Encyclopedia of Nanotechnology. Amsterdam, The Netherlands: Springer; 2012. https://doi.org/10.1007/978-94- 017-9780-1
48. 48. Jain KK. The role of nanobiotechnology in drug disco- very. Drug Discovery Today 2005;10:1435–42. https://doi. org/10.1016/S1359-6446(05)03573-7
49. 49. Bianco A, Kostarelos K, Prato M. Applications of carbon nano- tubes in drug delivery. Current Opinion in Chemical Biology 2005;9:674–9. https://doi.org/10.1016/j.cbpa.2005.10.005
50. 50. Liu K, Zhang J-J, Cheng F-F, Zheng T-T, Wang C, Zhu J-J. Green and facile synthesis of highly biocompatible graphe- ne nanosheets and its application for cellular imaging and drug delivery. J Mater Chem 2011;21:12034. https://doi. org/10.1039/c1jm10749f
51. 51. Zheng M, Liu S, Li J, Qu D, Zhao H, Guan X, et al. Integrating Oxaliplatin with Highly Luminescent Carbon Dots: An Unp- recedented Theranostic Agent for Personalized Medicine. Ad- vanced Materials 2014;26:3554–60. https://doi.org/10.1002/ adma.201306192
52. 52. [Mishra A, Kumar R, Mishra J, Dutta K, Ahlawat P, Kumar A, et al. Strategies facilitating the permeation of nanoparticles through blood-brain barrier: An insight towards the develop- ment of brain-targeted drug delivery system. Journal of Drug Delivery Science and Technology 2023;86:104694. https://doi. org/10.1016/j.jddst.2023.104694
53. 53. Fang J, Lai Y, Chiu T, Chen Y, Hu S, Chen S. Magnetic Core– Shell Nanocapsules with Dual-Targeting Capabilities and Co- Delivery of Multiple Drugs to Treat Brain Gliomas. Adv He- althcare Materials 2014;3:1250–60. https://doi.org/10.1002/ adhm.201300598
54. 54. Pedram M, Shamloo A, Alasty A, Ghafar-Zadeh E. Toward Epileptic Brain Region Detection Based on Magnetic Nano- particle Patterning. Sensors 2015;15:24409–27. https://doi. org/10.3390/s150924409
55. 55. Roet M, Hescham S-A, Jahanshahi A, Rutten BPF, Ani- keeva PO, Temel Y. Progress in neuromodulation of the brain: A role for magnetic nanoparticles? Progress in Neu- robiology 2019;177:1–14. https://doi.org/10.1016/j.pneuro- bio.2019.03.002
56. 56. Yafout M, Ousaid A, Khayati Y, El Otmani IS. Gold nano- particles as a drug delivery system for standard chemothe- rapeutics: A new lead for targeted pharmacological cancer treatments. Scientific African 2021;11:e00685. https://doi. org/10.1016/j.sciaf.2020.e00685
57. 57. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-Dependent Cytotoxicity of Gold Nanoparticles. Small 2007;3:1941–9. https://doi.org/10.1002/smll.200700378
58. 58. Kong F-Y, Zhang J-W, Li R-F, Wang Z-X, Wang W-J, Wang W. Unique Roles of Gold Nanoparticles in Drug Delivery, Tar- geting and Imaging Applications. Molecules 2017;22:1445. https://doi.org/10.3390/molecules22091445
59. 59. Khongkow M, Yata T, Boonrungsiman S, Ruktanonchai UR, Graham D, Namdee K. Surface modification of gold nano- particles with neuron-targeted exosome for enhanced blood– brain barrier penetration. Sci Rep 2019;9:8278. https://doi. org/10.1038/s41598-019-44569-6
60. 60. Kalluri R. The biology and function of exosomes in cancer. Journal of Clinical Investigation 2016;126:1208–15. https:// doi.org/10.1172/JCI81135
61. 61. Fais S, O’Driscoll L, Borras FE, Buzas E, Camussi G, Cappel- lo F, et al. Evidence-Based Clinical Use of Nanoscale Extra- cellular Vesicles in Nanomedicine. ACS Nano 2016;10:3886– 99. https://doi.org/10.1021/acsnano.5b08015
62. 62. Wiklander OPB, Nordin JZ, O’Loughlin A, Gustafsson Y, Corso G, Mäger I, et al. Extracellular vesicle in vivo biodist- ribution is determined by cell source, route of administration and targeting. J of Extracellular Vesicle 2015;4:26316. https:// doi.org/10.3402/jev.v4.26316
63. 63. Tian T, Zhang H-X, He C-P, Fan S, Zhu Y-L, Qi C, et al. Surfa- ce functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 2018;150:137–49. https://doi.org/10.1016/j.biomaterials.2017.10.012
64. 64. Sidoryk-Węgrzynowicz M, Dąbrowska-Bouta B, Sulkowski G, Strużyńska L. Nanosystems and exosomes as future app- roaches in treating multiple sclerosis. Eur J of Neuroscience 2021;54:7377–404. https://doi.org/10.1111/ejn.15478
65. 65. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Advanced Drug Delivery Reviews 2012;64:701–5. https://doi. org/10.1016/j.addr.2011.12.006
66. 66. Pearson RM, Casey LM, Hughes KR, Wang LZ, North MG, Getts DR, et al. Controlled Delivery of Single or Multiple An- tigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates. Molecular Therapy 2017;25:1655–64. https:// doi.org/10.1016/j.ymthe.2017.04.015
67. 67. Cappellano G, Woldetsadik AD, Orilieri E, Shivakumar Y, Rizzi M, Carniato F, et al. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encepha- lomyelitis. Vaccine 2014;32:5681–9. https://doi.org/10.1016/j. vaccine.2014.08.016
68. 68. Rittchen S, Boyd A, Burns A, Park J, Fahmy TM, Metcalfe S, et al. Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF). Biomaterials 2015;56:78– 85. https://doi.org/10.1016/j.biomaterials.2015.03.044
69. 69. Li PY, Bearoff F, Zhu P, Fan Z, Zhu Y, Fan M, et al. PEGy- lation enables subcutaneously administered nanoparticles to induce antigen-specific immune tolerance. J Control Release 2021;331:164–75. https://doi.org/10.1016/j.jcon- rel.2021.01.013
70. 70. Pei W, Wan X, Shahzad KA, Zhang L, Song S, Jin X, et al. Direct modulation of myelin-autoreactive CD4 + and CD8 + T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded major histocompatibility complexes, CD47 and multiple regulatory molecules. IJN 2018;Volume 13:3731–50.https://doi.org/10.2147/IJN.S164500
71. 71. McCarthy DP, Yap JW-T, Harp CT, Song WK, Chen J, Pearson RM, et al. An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy. Nanomedicine: Nanotech- nology, Biology and Medicine 2017;13:191–200. https://doi. org/10.1016/j.nano.2016.09.007
72. 72. Zhao X, Sun L, Wang J, Xu X, Ni S, Liu M, et al. Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy. Interna- tional Journal of Pharmaceutics 2023;644:123351. https://doi. org/10.1016/j.ijpharm.2023.123351
73. 73. Hayder M, Varilh M, Turrin C-O, Saoudi A, Caminade A-M, Poupot R, et al. Phosphorus-Based Dendrimer ABP Treats Neuroinflammation by Promoting IL-10-Producing CD4 + T Cells. Biomacromolecules 2015;16:3425–33. https://doi. org/10.1021/acs.biomac.5b00643
74. 74. Wegmann KW, Wagner CR, Whitham RH, Hinrichs DJ. Synthetic Peptide Dendrimers Block the Development and Expression of Experimental Allergic Encephalomyelitis. The Journal of Immunology 2008;181:3301–9. https://doi. org/10.4049/jimmunol.181.5.3301
75. 75. Shimizu K, Agata K, Takasugi S, Goto S, Narita Y, Asai T, et al. New strategy for MS treatment with autoantigen- modified liposomes and their therapeutic effect. J Control Release 2021;335:389–97. https://doi.org/10.1016/j.jcon- rel.2021.05.027
76. 76. Schmidt J, Metselaar JM, Wauben MHM, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glu- cocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003;126:1895–904. https://doi. org/10.1093/brain/awg176
77. 77. Gaillard PJ, Appeldoorn CCM, Rip J, Dorland R, van der Pol SMA, Kooij G, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a mo- del of neuroinflammation. J Control Release 2012;164:364–9. https://doi.org/10.1016/j.jconrel.2012.06.022
78. 78. Lee D-H, Rötger C, Appeldoorn CCM, Reijerkerk A, Glad- dines W, Gaillard PJ, et al. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycop- rotein induced experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2014;274:96–101. https://doi. org/10.1016/j.jneuroim.2014.06.025
79. 79. Gandomi N, Varshochian R, Atyabi F, Ghahremani MH, Sha- rifzadeh M, Amini M, et al. Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain- targeted delivery of medicines. Pharmaceutical Development and Technology 2017;22:426–35. https://doi.org/10.1080/108 37450.2016.1226901
80. 80. Esposito E, Cortesi R, Drechsler M, Fan J, Fu BM, Calde- ran L, et al. Nanoformulations for dimethyl fumarate: Physi- cochemical characterization and in vitro / in vivo behavior. European Journal of Pharmaceutics and Biopharmaceutics 2017;115:285–96. https://doi.org/10.1016/j.ejpb.2017.04.011
81. 81. Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Vitamin-Derived Nanolipoidal Carriers for Brain Deli- very of Dimethyl Fumarate: A Novel Approach with Preclini- cal Evidence. ACS Chem Neurosci 2017;8:1390–6. https://doi. org/10.1021/acschemneuro.7b00041
82. 82. Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Stearic acid based, systematically designed oral lipid nanoparticles for enhanced brain delivery of dimethyl fumara- te. Nanomedicine 2017;12:2607–21. https://doi.org/10.2217/ nnm-2017-0082
83. 83. Kumar P, Sharma G, Gupta V, Kaur R, Thakur K, Malik R, et al. Oral Delivery of Methylthioadenosine to the Brain Emp- loying Solid Lipid Nanoparticles: Pharmacokinetic, Behavi- oral, and Histopathological Evidences. AAPS PharmSciTech 2019;20:74. https://doi.org/10.1208/s12249-019-1296-0
84. 84. Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Enhanced Brain Delivery of Dimethyl Fumarate Emp- loying Tocopherol-Acetate-Based Nanolipidic Carriers: Evi- dence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies. ACS Chem Neurosci 2017;8:860–5. https:// doi.org/10.1021/acschemneuro.6b00428
85. 85. Kumar P, Sharma G, Gupta V, Kaur R, Thakur K, Malik R, et al. Preclinical Explorative Assessment of Dimethyl Fumarate-Ba- sed Biocompatible Nanolipoidal Carriers for the Management of Multiple Sclerosis. ACS Chem Neurosci 2018;9:1152–8. https://doi.org/10.1021/acschemneuro.7b00519
86. 86. Gadhave DG, Kokare CR. Nanostructured lipid carriers en- gineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Development and Industrial Pharmacy 2019;45:839–51.https://doi.org/10.1 080/03639045.2019.1576724
87. 87. Chen Y-W, Hwang KC, Yen C-C, Lai Y-L. Fullerene deri- vatives protect against oxidative stress in RAW 264.7 cells and ischemia-reperfused lungs. American Journal of Physi- ology-Regulatory, Integrative and Comparative Physiology 2004;287:R21–6. https://doi.org/10.1152/ajpregu.00310.2003
88. 88. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petro- vic-Stojkovic S, Puckett L, et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclero- sis. J Clin Invest 2008;118:1532–43. https://doi.org/10.1172/ JCI33464.
89. 89. Bonoiu A, Mahajan SD, Ye L, Kumar R, Ding H, Yong K-T, et al. MMP-9 gene silencing by a quantum dot–siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Research 2009;1282:142–55. https://doi.org/10.1016/j. brainres.2009.05.047
90. 90. Hess KL, Oh E, Tostanoski LH, Andorko JI, Susumu K, Deschamps JR, et al. Engineering Immunological Tolerance Using Quantum Dots to Tune the Density of Self-Antigen Display. Adv Funct Materials 2017;27:1700290. https://doi. org/10.1002/adfm.201700290
91. 91. Millward JM, Schnorr J, Taupitz M, Wagner S, Wuerfel JT, Infante-Duarte C. Iron Oxide Magnetic Nanoparticles High- light Early Involvement of the Choroid Plexus in Central Ner- vous System Inflammation. ASN Neuro 2013;5:AN20120081. https://doi.org/10.1042/AN20120081
92. 92. [Siegers GM, Krishnamoorthy S, Gonzalez-Lara LE, McFad- den C, Chen Y, Foster PJ. Pre-Labeling of Immune Cells in Normal Bone Marrow and Spleen for Subsequent Cell Tracking by MRI. Tomography 2016;2:26–34. https://doi. org/10.18383/j.tom.2016.00103
93. 93. Kirschbaum K, Sonner JK, Zeller MW, Deumelandt K, Bode J, Sharma R, et al. In vivo nanoparticle imaging of innate immu- ne cells can serve as a marker of disease severity in a model of multiple sclerosis. Proc Natl Acad Sci USA 2016;113:13227– 32. https://doi.org/10.1073/pnas.1609397113
94. 94. Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ. Nano- particle-mediated codelivery of myelin antigen and a toleroge- nic small molecule suppresses experimental autoimmune en- cephalomyelitis. Proc Natl Acad Sci USA 2012;109:11270–5. https://doi.org/10.1073/pnas.1120611109
95. 95. Aghaie T, Jazayeri MH, Avan A, Anissian A, Salari A. Gold nanoparticles and polyethylene glycol alleviate clinical symptoms and alter cytokine secretion in a mouse model of experimental autoimmune encephalomyelitis. IUBMB Life 2019;71:1313–21. https://doi.org/10.1002/iub.2045
96. 96. Nosratabadi R, Rastin M, Sankian M, Haghmorad D, Mahmo- udi M. Hyperforin-loaded gold nanoparticle alleviates expe- rimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells. Nanomedi- cine: Nanotechnology, Biology and Medicine 2016;12:1961– 71. https://doi.org/10.1016/j.nano.2016.04.001
97. 97. Hosseini Shamili F, Alibolandi M, Rafatpanah H, Abnous K, Mahmoudi M, Kalantari M, et al. Immunomodulatory pro- perties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score. J Control Release 2019;299:149–64. https://doi.org/10.1016/j.jconrel.2019.02.032
98. 98. Li Z, Liu F, He X, Yang X, Shan F, Feng J. Exosomes deri- ved from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. International Immu- nopharmacology 2019;67:268–80. https://doi.org/10.1016/j. intimp.2018.12.001
99. 99. Rajan TS, Giacoppo S, Diomede F, Ballerini P, Paolantonio M, Marchisio M, et al. The secretome of periodontal ligament stem cells from MS patients protects against EAE. Sci Rep 2016;6:38743. https://doi.org/10.1038/srep38743
100. 100. Clark K, Zhang S, Barthe S, Kumar P, Pivetti C, Kreutzberg N, et al. Placental Mesenchymal Stem Cell-Derived Extra- cellular Vesicles Promote Myelin Regeneration in an Animal Model of Multiple Sclerosis. Cells 2019;8:1497. https://doi. org/10.3390/cells8121497